Brokerage Outlook on Maruti Suzuki, GAIL, Rossari Biotech, and UPL After Q1 Results

Brokerage firm Morgan Stanley maintained an overweight rating on Maruti Suzuki post Q1 results, Jefferies downgraded GAIL India to underperform and maintained a buy rating on UPL.

We have collated a list of recommendations from top brokerage firms from ETNow and other sources:

Morgan Stanley on Maruti Suzuki: Overweight| Target Rs 11,164

Morgan Stanley maintained an overweight rating on Maruti Suzuki with a target of Rs 11,164 post-Q1 results. Q1 EBITDA was 4% below Morgan Stanley’s estimates.

The ramp-up of new models will drive market share gains. Mix improvement, commodity and currency tailwinds, and leverage gains will support margin expansion.

The global investment bank views this acquisition as a neutral to positive event.

Jefferies on GAIL India: Downgrade to underperform| Target Rs 105

Jefferies downgraded GAIL India to underperform with a target price of Rs 105. The June quarter was a weak print with misses in transmission and Petchem compensated by a beat in trading.

Elevated gas costs should cap Ebitda growth in transmission. Petrochemicals and LPG will drag on weak pricing. The risk-to-reward ratio is unfavorable.

Jefferies on UPL: Buy| Target Rs 800

Jefferies maintained a buy rating on UPL with a target price of Rs 800. The company reported a disappointing quarter.

There is pressure on volumes and pricing. The global investment bank slashed FY25-26 EPS by 9-10%, and FY24 cuts are sharper. The buy rating stays on an inexpensive PE ratio.

YES Securities on Rossari Biotech: Buy| Target Rs 1030

YES Securities maintained a buy rating on Rossari Biotech with a target price of Rs 1030. Rossari’s reported operating profits at Rs 57.7 crore.

The Ebitda margin stood at 14.1% (4Q: 13.4%) improved marginally due to lower employee costs. Rossari acquired 16% of the remaining stake in Tristar Intermediates for a consideration of Rs 16.9 cr.

Rossari has its R&D at the core and customization through which it aims to deliver growth in volatile macro scenarios. “We maintain a Buy rating with a revised target price of Rs 1,030,” said the note.

(Disclaimer: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times)

FOLLOW US ON GOOGLE NEWS

Read original article here

Denial of responsibility! Swift Telecast is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials, please contact us by email – swifttelecast.com. The content will be deleted within 24 hours.

Leave a Comment